The NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop heparan sulfate binding Lectenz®.
Lectenz Bio awarded NIH NIGMS SBIR Phase I
Category: Lectenz Bio News
Date: January 23, 2020
Author: dschulz